Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer

Summary

Endometrial cancer (EC) is a prevalent gynecological cancer with an escalating global incidence and a decreasing age of onset. In the era of precision medicine, there is an increasing emphasis on tailoring treatments to different populations to optimize the positive impact of clinical interventions. Fertility-sparing therapies (FST) are gaining popularity for early-stage, low-grade endometrial cancer due to mounting evidence supporting favorable oncologic and pregnancy outcomes. However, consensus regarding the feasibility of fertility-sparing therapy for similar low-risk grade-2 (G2) endometrioid adenocarcinoma remains elusive. Given the uncertainties surrounding fertility-preserving therapy in patients with moderately differentiated endometrial cancer, this study aims to investigate the optimal regimen of fertility-preserving therapy for patients with IAG2.

Eligibility

Inclusion Criteria:

* Endometrioid adenocarcinoma G2, diagnosis by pathological.
* The lesion is limited to the endometrium.
* FIGO (2009) staging is IA.
* Age less than 45.
* Strongly request to preserve fertility.
* Sign informed consent.

Exclusion Criteria:

* The tumor has invaded the muscle layer.
* FIGO (2009) stage IB or higher.
* Endometrioid adenocarcinoma G1, G3, or non-endometrioid cancer
* There are malignant tumors in other systems.
* Have contraindications for conservative treatment or drug use.
* Have been judged by the researcher to be unsuitable for childbearing.

Conditions3

Browse More Trials